Gamma-aminobutyric acid type A receptor alpha 6 beta 3 subtype (GABA_A receptor α6β3)

The GABA_A receptor α6β3 subtype is a specific isoform of the gamma-aminobutyric acid type A (GABA_A) receptor, a pentameric ligand-gated chloride channel that mediates the majority of fast inhibitory neurotransmission in the central nervous system [1.1.1, 1.1.2]. This subtype is characterized by the presence of the α6 and β3 subunits, with the α6 subunit being notably restricted in its expression, primarily found in the cerebellar granule cells and the trigeminal ganglia [1.2.1, 1.2.4]. Because of this localized expression, the α6β3 subtype has emerged as a promising therapeutic target for conditions involving trigeminal nerve activation, such as migraine and trigeminal neuralgia, as well as neuropsychiatric disorders like schizophrenia and essential tremor [1.1.2, 1.2.2]. Drugs targeting this receptor, such as positive allosteric modulators (PAMs) like Compound 6 (PZ-II-029), aim to enhance GABAergic inhibition to alleviate symptoms without the broad sedative effects associated with non-selective benzodiazepines [1.1.2, 1.4.1]. Research indicates that these receptors play a crucial role in both phasic and tonic inhibition, influencing motor coordination, sensory filtering, and the processing of pain signals [1.2.1, 1.3.3].

Other names

α6β3 GABA-A receptorGABRA6-GABRB3 receptor complexAlpha-6 beta-3 GABA-A receptorGABRA6/GABRB3

Positive allosteric modulation of the GABA-A receptor chloride channel, typically via the alpha 6 subunit or the alpha+beta- interface; Antagonism (e.g., furosemide).